Igor P. Bilinsky
Chief Operating OfficerDr. Igor P. Bilinsky, Ph.D, has been Chief Operating Officer at Iovance Biotherapeutics, Inc since March 15, 2021. He had been Chief Business Officer of Oncternal Therapeutics, Inc. since September 09, 2019. Dr. Bilinsky served as General Manager of Immuno-Oncology at Ignyta, Inc. from September 2015 to January 1, 2017 and its Senior Vice President of Research Operations from February, 2016 to January 1, 2017. Dr. Bilinsky was the Chief Operating Officer and Senior Vice President of AmpliPhi Biosciences Corporation from January 30, 2017 to January 14, 2019. Dr. Bilinsky served as Senior Vice President of Special Operations at Ignyta, Inc. from September 2015 to March 1, 2016. Dr. Bilinsky served as the Senior Vice President of Corporate Development at Vical Incorporated from October 2010 to September 8, 2015. He served as Vice President of Business Development and Special Operations at Halozyme Therapeutics from 2008 to 2010. He joined Halozyme in 2007 as Executive Director of Corporate Development and Special Operations. Dr. Bilinsky served as the Chief Executive Officer at Androclus Therapeutics Inc. from 2005 to 2007. He joined Androclus in 2004 as Chief Operating Officer. Prior to joining Ignyta, Dr. Bilinsky was Senior Vice President, Corporate Development at Vical Inc. Previously, Dr. Bilinsky was General Manager, Immuno-Oncology, and Senior Vice President, Special Operations and Research Operations, at Ignyta, Inc., a biotechnology company focused on precision medicine in oncology that was acquired by Roche. Dr. Bilinsky served as a Manager in the Healthcare practice of the Boston Consulting Group (BCG). Dr. Bilinsky served in positions of increasing responsibility as a management consultant, project leader and ultimately as principal in the healthcare practice of the Boston Consulting Group from 1999 to 2004, where he advised companies in the biotechnology, pharmaceutical and life science industries on business strategy, operational performance and mergers and acquisitions. Prior to joining the Boston Consulting Group, he was employed in research positions at Symyx Technologies and the Massachusetts Institute of Technology (MIT) Lincoln Laboratory. He has broad experience in strategic, operational and entrepreneurial management in biopharmaceutical companies, including immunology experience. He served as a Director of Androclus Therapeutics, Inc. Dr. Bilinsky holds a Ph.D. in Physics from Massachusetts Institute of Technology and a B.Sc. in Physics from Moscow Institute of Physics and Technology.
Positions
- Company NameIovance Biotherapeutics, Inc.Stock CodeIOVAPositionChief Operating OfficerColleagues
- FGFrederick G. VogtInterim CEO, President, General Counsel, Corporate Secretary & Director
- IDIain D. DukesIndependent Chairman of the Board
- CMCorleen M. RocheChief Financial Officer
- RKRaj K. PuriChief Regulatory Officer
- DGDaniel G. KirbyChief Commercial Officer
- RDRyan D. MaynardIndependent Director
- MWMichael WeiserIndependent Director
- CYCassian YeeMember of Scientific Advisory Board
